Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued
Reference number: GID-TA10309
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of entinostat for treating hormone receptor-positive breast cancer after hormonal therapy.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.